Treg infiltration in glioma: a hurdle for antiglioma immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment.CNS neuroscience & therapeutics · 2026
   Article
2. Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification.Frontiers in immunology · 2023
   Article
3. A Novel Prognostic Marker and Therapeutic Target Associated with Glioma Progression in a Tumor Immune Microenvironment.Journal of inflammation research · 2023
   Article
4. A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma.Medicina (Kaunas, Lithuania) · 2022
   Article
5. The immunosuppressive microenvironment and immunotherapy in human glioblastoma.Frontiers in immunology · 2022
   Review
6. Transcriptome profile and clinical characterization of ICOS expression in gliomas.Frontiers in oncology · 2022
   Article
7. Identification of a novel pyroptosis-related gene signature correlated with the prognosis of diffuse glioma patients.Annals of translational medicine · 2021
   Article
8. Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged.Cancers · 2020
   Review
9. High expression of stromal signatures correlated with macrophage infiltration, angiogenesis and poor prognosis in glioma microenvironment.PeerJ · 2020
   Article
10. Autologous and Pooled Tumor Lysates in Combined Immunotherapy of Patients with Glioblastoma.Sovremennye tekhnologii v meditsine · 2020
    Article
11. Immune-Related lncRNA Correlated with Transcription Factors Provide Strong Prognostic Prediction in Gliomas.Journal of oncology · 2020
    Article
12. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.Frontiers in immunology · 2018
    Review
13. Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.Cancer research · 2016
    Article
14. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.Neuro-oncology · 2015
    Article
15. Brain Tumor Immunotherapy: What have We Learned so Far?Frontiers in oncology · 2015
    Review
16. Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Future virology · 2013
    Article
17. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain.Clinical & developmental immunology · 2013
    Article

Corrections and comments

• Comment on
  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract